– USA, TX – Nacuity Pharmaceuticals, a clinical-stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts, and other ocular diseases caused by oxidative stress, today announced the appointment of Dr. Bob Ruffolo (Ph.D.) to its Board of Directors, bringing a wealth of experience in leading the identification, research, and development of disease treatments.
“We are honored to have Dr. Ruffolo join our board. His expertise in scientific discovery, business strategy and commercial development will be invaluable as we develop innovative solutions for patients who struggle with ocular diseases,” said Chairman, CEO, and Co-Founder, Halden Conner.
About Dr. Robert Ruffolo
Dr. Ruffolo currently serves as Chief Innovation Officer for Versicolor Technologies. He was President of R&D and SVP of Wyeth Pharmaceuticals from 2002 to 2008. Before Wyeth, Dr. Ruffolo was SVP in R&D at SmithKline Beecham Pharmaceuticals for 17 years. He played a significant role in the discovery and/or development of several marketed products, including carvedilol, ropinerole, dobutamine, and eprosartan, among others. Dr. Ruffolo has been recognized with several prestigious awards, including the Discoverer’s Award in 2008, for his pioneering work on the discovery of carvedilol for the treatment of congestive heart failure. Dr. Ruffolo currently serves as a Director at Sigilon Therapeutics, Elucida Oncology, Sapience Therapeutics, and Aridis Pharmaceuticals.
“With its diverse library of novel antioxidant molecules, Nacuity is well-positioned to deliver treatments for ocular diseases caused by oxidative stress, including retinitis pigmentosa and cataracts,” said Dr. Ruffolo. “I’m delighted to join Nacuity’s board to help support the team during this exciting time of clinical development and business growth.”
Dr. Ruffolo holds a B.S. in Pharmacy, and a Ph.D. in Pharmacology, both from The Ohio State University.
About Nacuity Pharmaceuticals
Nacuity Pharmaceuticals, Inc., is a Fort Worth, Texas-based clinical stage biopharmaceutical company focused on advancing treatments for ocular conditions involving oxidative stress. Oxidative stress has been implicated in a variety of ocular diseases, including retinitis pigmentosa, cataracts, age-related macular degeneration, diabetic retinopathy, and glaucoma. The company’s lead compound, NPI-001, is an orally administered antioxidant currently being evaluated in a Phase 1/2 study in patients suffering from retinitis pigmentosa associated with Usher syndrome. Nacuity expects to report interim results from this study during the fourth quarter of 2022. In preclinical animal studies, NPI-001 preserved photoreceptor cells and functionality. The company is also developing NPI-002 to slow cataract progression and expects to initiate a Phase 1/2 clinical study of NCI-002 during the fourth quarter of 2021.
For more information : https://www.nacuity.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
